Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
ثبت نشده
چکیده
PETACH TIKVA, Israel, May 3, 2017 /PRNewswire/ -Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on a Phase II clinical trial to evaluate its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH).
منابع مشابه
Nonalcoholic Fatty Liver Disease Treatment
Nonalcoholic fatty liver disease (NAFLD) is increasing in pediatric age group parallel to the growing prevalence of obesity and overweight all around the world. So changing in life style and interventions on obesogenic environment is cornerstone of NAFLD therapy in obese children. Some experts recommend that children and adolescents be encouraged to follow a low-fat, low-glycemic-index diet t...
متن کاملTreatment of non-alcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is very common in the United States, and in some patients it may lead to cirrhosis, liver failure, and liver cancer. NAFLD encompasses a spectrum of liver injury, ranging from steatosis to steatohepatitis, advanced fibrosis, and cirrhosis. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, histologically comprises steatosis, balloon degenera...
متن کاملRecurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is considered as a silent liver disease. The metabolic syndrome and its components are accounted as the ...
متن کاملبررسی اثر سیلی مارین در درمان استئاتوهپاتیت غیر الکلی
Background and purpose: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of increased liver enzymes. The world population are suffering from NAFLD (30% in IRAN, 20% - 40% in western countries, and 5% - 30% in Asia-Pacific). The prevalence of NAFLD is higher in hyperlipidemic, diabetic and obese people. This study assessed the preventive effect of sylmarin on the progre...
متن کاملPharmacotherapy for NASH: Current and emerging.
Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the progressive variant of NAFLD, non-alcoholic steatohepatitis (NASH), are at significantly increased risk of multisystem morbidity and mortality. However, there are currently no approved pharmacologic therapies for NASH....
متن کامل